How GLP-1 and GIP Work in Weight Loss Medications

For most of human history, "appetite" was a black box. People got hungry, then they ate, then they got full. We knew the body kept some sort of accounting — but the messages, the messengers, and the math behind them were invisible. Over the last forty years, that black box has cracked open. Researchers traced a handful of gut hormones, mapped where they bind in the brain, and learned how to mimic them with drugs. The result is the entire modern GLP-1 class — semaglutide, tirzepatide, and a growing pipeline of research compounds that target two, three, even four of these signals at once.

This guide walks through the biology in plain English: what GLP-1 and GIP actually do, why a drug that activates both works better than a drug that activates one, and where the science is going next.

The one-paragraph version

After you eat, your gut releases hormones — including GLP-1 and GIP — that tell your brain you're full, slow your stomach so food stays put longer, and prompt your pancreas to release insulin. GLP-1 medications mimic one of those signals. Tirzepatide mimics two. Investigational drugs in clinical trials are mimicking three. More signals, more fullness, more weight loss — but also more cost, more side effects, and (so far) no FDA-approved triple-receptor medications on the market.

The gut hormones that govern hunger

Your gut isn't passive plumbing. It's a sensing organ, lined with cells that release hormones the moment food arrives. Those hormones travel through the bloodstream to the pancreas, the stomach, and — most importantly for weight — the appetite-regulating centers of the brain. Three of them seem to matter most for modern obesity medicine.

GLP-1 (glucagon-like peptide-1)

GLP-1 is released by L-cells in the lower small intestine within minutes of eating. It does three things:

Slows gastric emptying. Food stays in your stomach longer, which mechanically prolongs fullness.
Triggers insulin release. The pancreas dumps insulin in response to rising blood sugar, but only when blood sugar is actually elevated — which is why GLP-1 medications don't usually cause hypoglycemia in non-diabetics.
Acts in the brain. GLP-1 receptors in the hypothalamus and brainstem dial down the drive to eat. This is the appetite-suppression effect patients describe most.

Natural GLP-1 lasts only a few minutes in the bloodstream — an enzyme called DPP-4 breaks it down almost immediately after release. Semaglutide and tirzepatide are engineered versions of GLP-1 that resist that enzyme, so a single weekly injection maintains steady levels for the full week.

GIP (glucose-dependent insulinotropic polypeptide)

GIP is the other major incretin hormone, released by K-cells in the upper small intestine. For decades, researchers thought GIP was redundant — it triggers insulin release like GLP-1, so why hit both?

The answer turned out to be that GIP does more than just insulin signaling. It plays a role in how fat tissue stores and burns energy, in glucagon regulation, and in central appetite control through different brain circuits than GLP-1 alone. When you activate the GIP receptor in addition to the GLP-1 receptor, the appetite-suppression effect compounds — and the GI side effects do too, but less than you'd predict from doubling the target from one to two receptors. Tirzepatide is the first and currently the only FDA-approved drug to take advantage of this combination.

Glucagon

Glucagon is the third character in this story, and it's often misunderstood. Most people first hear about glucagon as the hormone that raises blood sugar — the counterweight to insulin, released during fasting. That's true, but glucagon also accelerates how fast the liver burns fat and how much energy the body expends at rest.

Glucagon acts on glucagon receptors (GCGR), which are located on cells in the liver, kidneys, intestines, brain, and other areas throughout the body. A drug that activates GCGR in addition to GLP-1 and GIP doesn't just suppress appetite — it nudges the body's energy expenditure upward. That's the rationale behind the next generation of investigational triple-receptor drugs in clinical trials. None of them are FDA-approved as of July 2026, and several are still in Phase 3 testing.

Why hitting two receptors works better than one

The dominant pivotal trials are STEP 1 (semaglutide, single GLP-1 agonist) and SURMOUNT-1 (tirzepatide, dual GLP-1 + GIP agonist). Both ran for over a year (about 68–72 weeks), both enrolled adults with obesity, both combined medication with lifestyle counseling. While the results of separate trials do not provide a direct comparison, the table below summarizes the findings.

Trial	Medication	Mechanism	Average weight loss
STEP 1	Wegovy® (semaglutide 2.4 mg)	GLP-1 agonist	14.9% body weight reduction in 68 weeks
SURMOUNT-1	Zepbound® (tirzepatide 15 mg)	GLP-1 + GIP dual agonist	20.9% body weight reduction in 72 weeks

For a 220-lb starting weight, that's roughly 33 lbs lost on semaglutide vs 46 lbs on tirzepatide. The dual-receptor mechanism is the main reason for the gap.

About the figures in this article

Outcomes referenced above are from published clinical trials of FDA-approved Wegovy® (semaglutide; STEP 1, Novo Nordisk) and Zepbound® (tirzepatide; SURMOUNT-1, Eli Lilly). Those results were observed with the FDA-approved products studied in those trials and have not been clinically established for compounded medications. Individual outcomes vary.

The reason dual activation works better isn't just additive — it's that the two receptors do different things in different tissues. GLP-1 mostly works on the brain's appetite centers and on stomach emptying. GIP mostly works on insulin sensitivity and fat metabolism. Combining them lets the medication push on the body's energy balance from multiple angles at once, which is why most patients describe tirzepatide as both more effective and (somewhat counterintuitively) more comfortable per pound lost.

Ready to see if you qualify?

A licensed Pallas provider can review your health history and confirm eligibility in under 2 minutes.

Start your intake →

A quick tour of the receptors at work

Imagine you finish a normal meal. Here's what's happening in your gut and brain over the next 90 minutes, with and without a GLP-1 medication.

Without medication:

Food hits your small intestine. L-cells and K-cells release GLP-1 and GIP.
Within 5 minutes, DPP-4 starts breaking down both hormones. They're nearly gone in 10–15 minutes.
Your stomach empties at its normal pace. Hunger returns 3–4 hours later.

On a GLP-1 medication (semaglutide):

Same release of natural GLP-1 and GIP from your gut.
The medication is already circulating at steady levels — your GLP-1 receptors are continuously activated whether you've just eaten or not.
Your stomach empties more slowly after eating. Fullness lasts hours longer than it normally would.
Hunger between meals is dramatically reduced. You eat less at the next meal without consciously trying.

On a dual GLP-1/GIP medication (tirzepatide):

Same gut release plus continuous activation of both GLP-1 and GIP receptors.
The combined effect on satiety signaling is stronger than GLP-1 alone.
Fat tissue handles incoming nutrients differently — GIP affects how energy gets stored.
Dual activation of GLP-1 and GIP receptors translates to reduced appetite and decreased calorie intake.

Cravings, particularly for high-fat and high-sugar foods, are often reported as quiet or silent with tirzepatide or semaglutide. This is why patients sometimes describe the experience as "food noise turning off." The brain stops pestering you for food because the hormonal signal that normally triggers food-seeking behavior is already saturated.

Where the science is going next

The field has been on a clear trajectory for fifteen years: each generation of obesity medication has added receptors and produced more weight loss. Semaglutide hit one receptor. Tirzepatide hits two. The next wave of investigational drugs in Phase 3 trials hit three — adding the glucagon receptor to GLP-1 and GIP.

Early-phase results from these triple-receptor compounds have been notable, with some trials reporting average weight loss exceeding what tirzepatide produced in SURMOUNT-1. But several caveats matter:

None of these drugs are FDA-approved as of July 2026. They are investigational and only available through clinical trials.
Triple-receptor drugs add complexity, not just effectiveness. Glucagon activation has metabolic effects — on heart rate, on the liver, on lean mass — that researchers are still characterizing.
The risk-benefit profile gets harder to evaluate with each receptor added. Regulators will want long-term safety data before approval.
Approval timelines are typically multi-year. Even if Phase 3 trials succeed, an FDA-approved triple-receptor medication is likely years away from a pharmacy shelf.

For now, the highest-evidence weight loss medications available to patients are the ones we've already covered: semaglutide and tirzepatide, both FDA-approved, both with extensive published trial data, both available as brand-name (Wegovy®, Zepbound®) and as compounded preparations through US-licensed pharmacies. We've written a direct comparison of semaglutide and tirzepatide if you're trying to choose between them.

Frequently asked questions

Some GLP-1 medications are peptides. Semaglutide is a synthetic analog of a hormone your body already produces. It is engineered to resist the enzyme (DPP-4) that breaks down natural GLP-1, which is why it lasts a week per injection instead of minutes. GLP-1 medications are not "peptide therapy" in the wellness-industry sense of that term — they are FDA-approved hormone-analog medications prescribed to millions of patients for managing weight, type 2 diabetes, or both.

Tirzepatide activates two receptors (GLP-1 and GIP) instead of one. The dual mechanism produces stronger satiety signaling in the brain and affects fat metabolism through GIP-specific pathways. Average weight loss in pivotal trials was about 6 percentage points higher for tirzepatide 15 mg (20.9%) vs semaglutide 2.4 mg (14.9%).

Not as of July 2026. Triple-receptor compounds (adding the glucagon receptor) are in Phase 3 clinical trials, but none have received FDA approval. The three FDA-approved injections for chronic weight management include semaglutide (Wegovy^®), tirzepatide (Zepbound^®), and liraglutide (Saxenda^®).

Most patients reach a weight plateau 12–18 months into therapy. This isn't usually "tolerance" in the pharmacological sense — it's the body settling at a new equilibrium where calorie intake matches expenditure. Weight regain after stopping the medication is well-documented (STEP 4 extension trial), which is why most healthcare providers recommend long-term treatment for obesity, similar to treating other chronic conditions like high blood pressure or cholesterol.

Not yet for the dual class. There is currently no FDA-approved oral version of tirzepatide or any dual GLP-1/GIP agonist. However, some GLP-1 medications are available as daily tablets, including oral semaglutide (as Wegovy^® and Ozempic^®). Orforglipron, sold as Foundayo^®, is another oral GLP-1 medication approved for weight loss.

Bottom line: Modern obesity medicine works because researchers learned to mimic the gut hormones your body uses to control appetite. The more of those signals a drug activates, the stronger the effect — but more receptors also mean more complexity and longer development timelines. FDA-approved options (semaglutide and tirzepatide) are highly effective for most patients; whichever you start with, the science behind it has been studied for decades.

Curious which medication fits your situation?

A licensed Pallas provider can review your goals and health history, then recommend the right starting point. It takes about 2 minutes.